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toxicity was seen between patients with SCN involvement and 
those without,irrespective of the location of the primary 
tumor.  
 
Conclusion: In esophageal cancer treated with definitive 
chemoradiation, number of affected lymph nodes is an 
important prognostic factor, while involvement of a 
supraclavicular lymph node is not. The supraclavicular lymph 
node should beconsidered a regional lymph node and treated 
with curative intend if the total number of involved lymph 
nodes is limited, irrespective of the site of the primary 
tumor. 
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Purpose or Objective: To define the role of radiation dose 
on overall survival (OS) in pancreatic adenocarcinoma (PAC) 
patients treated with adjuvant chemoradiotherapy (CRT). 
 
Material and Methods: A total of 518 patients from different 
centers, completely resected with macroscopically negative 
margins (R0-1) for PAC (T1-3; N0-1; M0) and treated with 
adjuvant CRT, were retrospectively reviewed. Patients with 
metastatic or unresectable disease at surgery, macroscopic 
residual disease (R2), treated with intraoperative 
radiotherapy (IORT), dead within 60 days of surgery and 
without a histological diagnosis of ductal carcinoma were 
excluded. Only 142 patients received adjuvant 
chemotherapy. 
 
Results: With 35 months of median follow-up, median OS was 
23.0 months after adjuvant CRT with dose ≥ 45 Gy versus 
13.0 months with dose < 45 Gy (p < 0.001); 5-year OS was 
21.9% versus 3.8%, respectively. Among prognostic factors, 
higher Ca19-9 levels (>90; p<0.001), higher tumor grade (G3-
4, p = 0.017), R1 resection (p = 0.003), higher pT stage (p = 
0.002) and positive nodes (p < 0.001) can be identified as 
negative. Multivariate analysis (HR: 0.52, 0.34-0.77; p = 
0.001) proved the positive impact of higher dose.  
 
Conclusion: A significant impact of CRT dose on OS was 
pointed out by the results of this analysis. The randomized 
trials on adjuvant CRT in PAC, in which a relatively low-dose 
of radiation (40 Gy, split course) was used, may have had 
conflicting results due to this bias.  
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Purpose or Objective: To compare long-term outcomes of 
chemoradiotherapy between young and elderly (≥70 years) 
oesophageal cancer patients treated with curative intent. 
 
Material and Methods: Oesophageal cancer patients treated 
between 1998 and 2013 in our institute with neoadjuvant 
(nCRT) or definitive (dCRT) chemoradiotherapy were 
retrospectively analysed. nCRT consisted of 36-50Gy with 
concurrent 5-fluorouracil/cisplatin or 41.4Gy with concurrent 
carboplatin/paclitaxel. dCRT consisted of 50Gy with 
concurrent fluorouracil/cisplatin or 50.4Gy with concurrent 
carboplatin/paclitaxel. Overall survival (OS), disease-free 
survival (DFS) and locoregional control (LRC) were compared 
between older (>70 years) and younger patients (< 70 years). 
Cox models were used to obtain adjusted hazard ratios (HR) 
and 95% confidence intervals (CI). 
 
Results: The cohort consisted of 253 patients with a median 
follow up of 4.3 years. A group of 182 patients (72%) was < 70 
years (median age 60). The remaining 71 patients were >70 
years (median age 75). The two age groups (younger vs. 
older) differed significantly regarding smoking (59% vs. 31%; 
p<0.001), alcohol abuse (64% vs. 46%; p=0.007), Charlson 
comorbidity index (median 0 vs. 1; p=0.001) and weight loss 
prior to CRT (median 4 vs. 3 kgs; p=0.038). Most patients had 
stage IIA-IIIA disease (82%). Distribution of tumour stages was 
similar in the two age groups (stage IIA: 27% vs. 24%, stage 
IIB: 4% vs. 4%, stage IIIA: 51% vs. 55%).  
Initial treatment was nCRT with the intent to proceed to 
surgery in 169 patients, whereas 84 patients were planned 
for dCRT. Although surgery was the intent, 15% of the 
younger nCRT patients were not operated versus 35% of the 
older nCRT patients (p=0.01). Reasons to withhold surgery in 
the younger versus older patients were tumour progression 
(10% vs. 14%), toxicity (2% vs. 11%) or patient's own choice 
(3% vs. 11%), p=0.01. At baseline, there was a significant 
difference in the distribution of the final treatment given 
(nCRT + surgery, dCRT or nCRT without surgery; p<0.001).  
For the entire study population, OS at 3-years was 42%. In the 
multivariable analysis, no difference was found in OS 
between the two age groups (old vs. young; HR 0.72, 95% CI 
0.49–1.07, p=0.10). In the older age group, DFS (HR 0.66, 95% 
CI 0.45–0.98, p=0.04) and LRC (HR 0.43, 95% CI 0.23–0.82, 
p=0.01) were significantly better than in the younger age 
group. 
 
Conclusion: Elderly oesophageal cancer patients (>70 years) 
treated with neoadjuvant chemoradiotherapy followed by 
surgery or definitive chemoradiotherapy had long-term 
outcomes which did not differ from the outcomes of their 
younger counterparts. For oesophageal cancer patients, 
advanced age alone should not be a contraindication for 
chemoradiotherapy as a part of treatment with curative 
intent. 
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